ES2721477T3 - Materiales y métodos para evaluar la progresión del cáncer de próstata - Google Patents
Materiales y métodos para evaluar la progresión del cáncer de próstata Download PDFInfo
- Publication number
- ES2721477T3 ES2721477T3 ES15739712T ES15739712T ES2721477T3 ES 2721477 T3 ES2721477 T3 ES 2721477T3 ES 15739712 T ES15739712 T ES 15739712T ES 15739712 T ES15739712 T ES 15739712T ES 2721477 T3 ES2721477 T3 ES 2721477T3
- Authority
- ES
- Spain
- Prior art keywords
- equal
- patient
- fgfr1
- gain
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Abstract
Un método para distinguir entre un paciente con adenocarcinoma prostático agresivo y un paciente con adenocarcinoma prostático indolente, método que comprende: (a) poner en contacto una muestra del paciente con un conjunto de sondas etiquetadas de manera detectable que comprende una sonda específica de locus para MYC, una sonda específica de locus para FGFR1 y una sonda de separación para ERG, en condiciones de hibridación, en donde se utiliza la sonda específica de locus para FGFR1 para determinar el % de pérdida de FGFR1, (b) determinar la presencia de una anomalía cromosómica en la muestra, en donde (i) un % de ganancia de MYC (el % de ganancia es el % de células con números de copias de MYC > 2) superior o igual a dos hasta inferior o igual a 30, (ii) un % de pérdida de FGFR1 (el % de pérdida es el % de células con números de copias de FGFR < 2) superior o igual a 15 hasta inferior o igual a 40, (iii) un % de ganancia de FGFR1 (el % de ganancia es el % de células con números de copias de FGFR > 2) superior o igual a dos hasta inferior o igual a 46, y/o (iv) un ERG 2+Edel superior o igual a uno hasta inferior o igual a 30, indica que el paciente tiene un alto riesgo de desarrollar un adenocarcinoma prostático agresivo y en donde la ausencia de cualquiera de (i)-(iv) anterior indica que el paciente tiene un adenocarcinoma prostático indolente, tras lo cual un paciente con adenocarcinoma prostático agresivo se distingue de un paciente con adenocarcinoma prostático indolente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462020990P | 2014-07-03 | 2014-07-03 | |
PCT/US2015/038761 WO2016004165A1 (en) | 2014-07-03 | 2015-07-01 | Materials and methods for assessing progression of prostate cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2721477T3 true ES2721477T3 (es) | 2019-07-31 |
Family
ID=53716562
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES15739712T Active ES2721477T3 (es) | 2014-07-03 | 2015-07-01 | Materiales y métodos para evaluar la progresión del cáncer de próstata |
Country Status (6)
Country | Link |
---|---|
US (3) | US9994912B2 (es) |
EP (2) | EP3164504B1 (es) |
JP (1) | JP6683633B2 (es) |
CN (1) | CN106574307A (es) |
ES (1) | ES2721477T3 (es) |
WO (1) | WO2016004165A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7254020B2 (ja) | 2016-12-13 | 2023-04-07 | ユニバーシティ オブ ピッツバーグ -オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 融合遺伝子を含有するがんを治療する方法 |
US11530451B2 (en) * | 2018-03-02 | 2022-12-20 | The Johns Hopkins University | Methods for prostate cancer detection |
WO2020023213A1 (en) * | 2018-07-27 | 2020-01-30 | Ventana Medical Systems, Inc. | Systems for automated in situ hybridization analysis |
CN109321569B (zh) * | 2018-10-29 | 2022-04-12 | 迈杰转化医学研究(苏州)有限公司 | 一种引物探针组合物及其应用 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5756696A (en) | 1986-01-16 | 1998-05-26 | Regents Of The University Of California | Compositions for chromosome-specific staining |
US5491224A (en) | 1990-09-20 | 1996-02-13 | Bittner; Michael L. | Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture |
ES2161715T3 (es) | 1992-03-04 | 2001-12-16 | Univ California | Hibridacion genomica comparativa (hgc). |
US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
US5658730A (en) | 1994-12-23 | 1997-08-19 | Ctrc Research Foundation | Methods of human prostate cancer diagnosis |
US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
US7037667B1 (en) | 1998-06-01 | 2006-05-02 | Agensys, Inc. | Tumor antigen useful in diagnosis and therapy of prostate and colon cancer |
US6613510B2 (en) | 1999-04-28 | 2003-09-02 | Mayo Foundation For Medical Education And Research | Methods and probe sets for determining prostate cancer prognosis |
WO2000077258A1 (en) | 1999-06-10 | 2000-12-21 | Sloan-Kettering Institute For Cancer Research | Markers for prostate cancer |
DE10063112A1 (de) | 2000-12-18 | 2002-06-20 | Bayer Ag | Verfahren zur Erhöhung der klinischen Spezifität bei der Detektion von Tumoren und ihren Vorstufen durch simultane Messung von mindestens zwei verschiedenen molekularen Markern |
WO2002100246A2 (en) | 2001-06-12 | 2002-12-19 | Board Of Regents, The University Of Texas System | Methods of detecting, diagnosing and treating cancer and identifying neoplastic progression |
US20070237770A1 (en) | 2001-11-30 | 2007-10-11 | Albert Lai | Novel compositions and methods in cancer |
ES2685702T3 (es) | 2002-03-13 | 2018-10-10 | Genomic Health, Inc. | Obtención de perfil de expresión génica en tejidos tumorales biopsiados |
US7604965B2 (en) | 2003-04-03 | 2009-10-20 | Fluidigm Corporation | Thermal reaction device and method for using the same |
CA2550429A1 (en) | 2004-02-06 | 2005-08-25 | Health Research, Inc. | Method of prognosis of metastasis by detection of fra12e fragile site within the smrt gene/locus at chromosome 12q24 |
AU2005245815B2 (en) | 2004-05-07 | 2011-06-09 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer |
CA2491067A1 (en) | 2004-12-24 | 2006-06-24 | Stichting Katholieke Universiteit | Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer |
WO2006091776A2 (en) | 2005-02-25 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Biomarkers for predicting prostate cancer progression |
EP1910557A2 (en) | 2005-04-07 | 2008-04-16 | Chiron Corporation | Cancer-related genes |
US9957569B2 (en) | 2005-09-12 | 2018-05-01 | The Regents Of The University Of Michigan | Recurrent gene fusions in prostate cancer |
EP2612870A1 (en) | 2005-09-12 | 2013-07-10 | The Regents of the University of Michigan | Recurrent gene fusions in prostate cancer |
US7812143B2 (en) | 2006-03-31 | 2010-10-12 | Memorial Sloan-Kettering Cancer Center | Biomarkers for cancer treatment |
FI20060751A0 (fi) | 2006-08-23 | 2006-08-23 | Valtion Teknillinen | Menetelmä prostatasyövän hoitoon ja mainitusta menetelmästä hyödyntävien potilaiden seulonta |
WO2008121132A2 (en) | 2007-03-30 | 2008-10-09 | Source Precision Medicine, Inc. D/B/A Source Mdx | Gene expression profiling for identification, monitoring, and treatment of prostate cancer |
US9303291B2 (en) | 2007-07-06 | 2016-04-05 | The Regents Of The University Of Michigan | MIPOL1-ETV1 gene rearrangements |
US8148078B2 (en) | 2007-09-07 | 2012-04-03 | Fluidigm Corporation | Copy number variation determination, methods and systems |
WO2009061297A1 (en) | 2007-11-06 | 2009-05-14 | Source Precision Medicine, Inc. | Gene expression profiling for identification of cancer |
JP5781922B2 (ja) | 2008-04-10 | 2015-09-24 | ザ ヘンリー エム.ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン,インコーポレーテッド | Erg遺伝子発現における前立腺癌特異的変化ならびにそれらの変化に基づく検出および治療方法 |
WO2009140741A1 (en) | 2008-05-23 | 2009-11-26 | The University Of Queensland | Agents and methods for diagnosing the presence or risk of prostate cancer |
CN102084004B (zh) | 2008-05-27 | 2016-01-20 | 丹麦达科有限公司 | 杂交组合物和方法 |
GB0809689D0 (en) | 2008-05-28 | 2008-07-02 | Cancer Res Inst Royal | Markers for prostate cancee |
EP2405022A3 (en) | 2008-07-08 | 2012-05-02 | Genomic Health, Inc. | Gene expression profiling for predicting the survivability of prostate cancer subjects |
CA2730614A1 (en) | 2008-07-16 | 2010-01-21 | Dana-Farber Cancer Institute | Signatures and pcdeterminants associated with prostate cancer and methods of use thereof |
WO2010056993A2 (en) | 2008-11-14 | 2010-05-20 | Emory University | Prostate cancer biomarkers to predict recurrence and metastatic potential |
US20120041274A1 (en) | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
US20120015839A1 (en) | 2009-01-09 | 2012-01-19 | The Regents Of The University Of Michigan | Recurrent gene fusions in cancer |
EP2380025B1 (en) | 2009-01-14 | 2013-09-11 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Ratio based biomarkers and methods of use thereof |
WO2010099577A1 (en) | 2009-03-04 | 2010-09-10 | The University Of Queensland | Cancer biomarkers and uses therefor |
WO2010102277A2 (en) | 2009-03-06 | 2010-09-10 | Cornell University | Methods of diagnosing and treating prostate cancer characterized by ndrg1-erg fusion |
US8993604B2 (en) | 2009-06-30 | 2015-03-31 | Siga Technologies, Inc. | Treatment and prevention of dengue virus infections |
US20130005837A1 (en) | 2009-12-31 | 2013-01-03 | Emory University | Cancer biomarkers to predict recurrence and metastatic potential |
CA2696545C (en) * | 2010-03-15 | 2019-08-06 | Queen's University At Kingston | Methods, probe sets, and kits for detection of deletion of tumor suppressor genes by fluorescence in situ hybridization |
EP2569624B1 (en) * | 2010-05-10 | 2017-03-15 | Mayo Foundation for Medical Education and Research | Detection of chromosomal abnormalities associated with endometrial cancer |
GB201012590D0 (en) | 2010-07-27 | 2010-09-08 | Queen Mary & Westfield College | Methods for diagnosing cancer |
US20120220672A1 (en) | 2011-02-24 | 2012-08-30 | Ventana Medical Systems, Inc. | Presence of ERG Gene Rearrangements and Protein Over-expression in Low Grade PIN (LG-PIN) in Prostate Biopsies |
CN104169425A (zh) | 2011-03-09 | 2014-11-26 | 理查德·G·佩斯泰尔 | 前列腺癌细胞系、遗传标志及其用途 |
WO2012125805A2 (en) | 2011-03-17 | 2012-09-20 | The Brigham And Women's Hospital, Inc. | Protein biomarkers for the diagnosis of prostate cancer |
EP2699696B1 (en) | 2011-04-18 | 2018-06-13 | Cornell University | Molecular subtyping, prognosis and treatment of prostate cancer |
WO2013033073A1 (en) | 2011-08-31 | 2013-03-07 | Ventana Medical Systems, Inc. | Expression of ets related gene (erg) and phosphatase and tensin homolog (pten) correlates with prostate cancer capsular penetration |
BR112014013544A2 (pt) | 2011-12-30 | 2017-06-13 | Abbott Molecular Inc | materiais e métodos para diagnose, prognose e avaliação do tratamento terapêutico/profilático de câncer da próstata |
WO2013173463A1 (en) | 2012-05-15 | 2013-11-21 | Cornell University | Erg/tff3/hmwck triple immunostain for detection of prostate cancer |
EP2695950A1 (en) | 2012-08-10 | 2014-02-12 | Blackfield AG | Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor |
CA2884737A1 (en) | 2012-08-16 | 2014-02-20 | The Trustees Of Columbia University In The City Of New York | Diagnostic markers of indolent prostate cancer |
WO2014159797A1 (en) * | 2013-03-14 | 2014-10-02 | Abbott Molecular Inc. | Cell preparations and cell supports and their use in theranosis |
-
2015
- 2015-06-30 US US14/788,195 patent/US9994912B2/en not_active Expired - Fee Related
- 2015-07-01 EP EP15739712.6A patent/EP3164504B1/en not_active Not-in-force
- 2015-07-01 JP JP2016575857A patent/JP6683633B2/ja not_active Expired - Fee Related
- 2015-07-01 CN CN201580046512.4A patent/CN106574307A/zh active Pending
- 2015-07-01 ES ES15739712T patent/ES2721477T3/es active Active
- 2015-07-01 WO PCT/US2015/038761 patent/WO2016004165A1/en active Application Filing
- 2015-07-01 EP EP18248085.5A patent/EP3530751A1/en not_active Withdrawn
-
2018
- 2018-06-11 US US16/005,228 patent/US10604812B2/en not_active Expired - Fee Related
-
2020
- 2020-02-20 US US16/796,026 patent/US20200199687A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2016004165A1 (en) | 2016-01-07 |
JP6683633B2 (ja) | 2020-04-22 |
CN106574307A (zh) | 2017-04-19 |
US10604812B2 (en) | 2020-03-31 |
US20160002735A1 (en) | 2016-01-07 |
US20180291466A1 (en) | 2018-10-11 |
JP2017521068A (ja) | 2017-08-03 |
US20200199687A1 (en) | 2020-06-25 |
EP3530751A1 (en) | 2019-08-28 |
EP3164504A1 (en) | 2017-05-10 |
EP3164504B1 (en) | 2019-02-20 |
US9994912B2 (en) | 2018-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP17025787A (es) | Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr | |
BR112017007965A2 (pt) | método implantado por computador para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; aparelho para inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; meio de armazenamento não transitório; programa de computador; kits para medir níveis de expressão de três ou mais genes-alvo da via de sinalização celular de tgf-b em uma amostra de um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; inferir a atividade de uma via de sinalização celular de tgf-b em um indivíduo; e uso do kit | |
ES2721477T3 (es) | Materiales y métodos para evaluar la progresión del cáncer de próstata | |
AR097542A1 (es) | Métodos y sistemas para la evaluación de la permeabilidad y la porosidad de la roca y la composición de los fluidos | |
MX2016007333A (es) | Clasificacion de cancer de prostata. | |
RU2013146242A (ru) | Fgfr и его лиганды в качестве биомаркеров рака молочной железы у hr-положительных индивидуумов | |
GB2545361A (en) | Protein biomarker panels for detecting colorectal cancer and advanced adenoma | |
EP4293358A3 (en) | Volatile organic compounds as cancer biomarkers | |
Zhang et al. | Elevated levels of autophagy-related marker ULK1 and mitochondrion-associated autophagy inhibitor LRPPRC are associated with biochemical progression and overall survival after androgen deprivation therapy in patients with metastatic prostate cancer | |
AR099856A1 (es) | Métodos para diagnosticar y tratar la enfermedad de intestino inflamado | |
CO2019011359A2 (es) | Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii | |
BR112019025056A2 (pt) | Inibidores de fgfr2 para o tratamento de colangiocarcinoma | |
EP3686290A3 (en) | Method and kits for identifying of cdk9 inhibitors for the treatment of cancer | |
MX2018013621A (es) | Metodo, matriz y uso de estos. | |
WO2014184679A3 (en) | Method for the prognosis and treatment of renal cell carcinoma metastasis | |
MX2019008911A (es) | Metodos, matrices y usos de estos. | |
WO2015092046A3 (en) | Prostate cancer biomarkers | |
MY193895A (en) | Combination test for colorectal cancer | |
WO2015095862A3 (en) | Microrna biomarkers for ovarian cancer | |
WO2015091575A3 (en) | Different levels in blood cell samples of emt-markers for the diagnosis of cancer, in particular of colorectal (crc) and pancreatic (pc) cancer | |
BR112019006862A2 (pt) | dispositivo de análise e método para testagem de uma amostra | |
MY193531A (en) | Assays and methods for selecting a treatment regimen for a subject with leukemia | |
MY195697A (en) | Method of Prognosing and Predicting Breast Cancer Recurrence, Markers Employed Therein and Kit Thereof | |
CL2023000509A1 (es) | Composiciones y métodos para tratar la endometriosis | |
ATE545867T1 (de) | I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom |